Related references
Note: Only part of the references are listed.Self-Adjuvanting Multicomponent Cancer Vaccine Candidates Combining Per-Glycosylated MUC1 Glycopeptides and the Toll-like Receptor 2 Agonist Pam(3)CysSer
Brendan L. Wilkinson et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
Mechanisms of Leukocyte Transendothelial Migration
William A. Muller
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Antibody-Dependent Cell Cytotoxicity Synapses Form in Mice during Tumor-Specific Antibody Immunotherapy
Pascale Hubert et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Towards a Fully Synthetic MUC1-Based Anticancer Vaccine: Efficient Conjugation of Glycopeptides with Mono-, Di-, and Tetravalent Lipopeptides Using Click Chemistry
Hui Cai et al.
CHEMISTRY-A EUROPEAN JOURNAL (2011)
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2011)
Seromic profiling of colorectal cancer patients with novel glycopeptide microarray
Johannes W. Pedersen et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Autoantibodies to Tailor-Made Panels of Tumor-Associated Antigens in Breast Carcinoma
Ettie Piura et al.
JOURNAL OF ONCOLOGY (2011)
Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis
Ola Blixt et al.
BREAST CANCER RESEARCH (2011)
Synthetic Antitumor Vaccines from Tetanus Toxoid Conjugates of MUC1 Glycopeptides with the Thomsen-Friedenreich Antigen and a Fluorine-Substituted Analogue
Anja Hoffmann-Roder et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Fully Synthetic Vaccines Consisting of Tumor-Associated MUC1 Glycopeptides and a Lipopeptide Ligand of the Toll-like Receptor 2
Anton Kaiser et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers
Nicolas Jonckheere et al.
BIOCHIMIE (2010)
Mumps and ovarian cancer: modern interpretation of an historic association
Daniel W. Cramer et al.
CANCER CAUSES & CONTROL (2010)
CA 15-3: Uses and limitation as a biomarker for breast cancer
Michael J. Duffy et al.
CLINICA CHIMICA ACTA (2010)
Sweetening the Pot: Adding Glycosylation to the Biomarker Discovery Equation
Penelope M. Drake et al.
CLINICAL CHEMISTRY (2010)
Vaccine-induced antibody responses in patients with carcinoma
Silvia von Mensdorff-Pouilly
EXPERT REVIEW OF VACCINES (2010)
Expression of aberrantly glycosylated Mucin-1 in ovarian cancer
Catharina H. M. J. Van Elssen et al.
HISTOPATHOLOGY (2010)
Glycan changes: cancer metastasis and anti-cancer vaccines
Min Li et al.
JOURNAL OF BIOSCIENCES (2010)
Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis
Qicheng Zhao et al.
MOLECULAR CANCER (2010)
The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF
M. E. Behrens et al.
ONCOGENE (2010)
Oncogenic function of the MUC1 receptor subunit in gene regulation
D. Kufe
ONCOGENE (2010)
Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation
Adam M. Farkas et al.
SEMINARS IN IMMUNOLOGY (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Tumour-associated carbohydrate antigens in breast cancer
Aurelie Cazet et al.
BREAST CANCER RESEARCH (2010)
A Synthetic Vaccine Consisting of a Tumor-Associated Sialyl-T-N-MUC1 Tandem-Repeat Glycopeptide and Tetanus Toxoid: Induction of a Strong and Highly Selective Immune Response
Anton Kaiser et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2009)
A genetic variant of immunoglobulin γ2 is strongly associated with immunity to mucin 1 in patients with breast cancer
Janardan P. Pandey et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
MUC1-Induced Transcriptional Programs Associated with Tumorigenesis Predict Outcome in Breast and Lung Cancer
Nikolai N. Khodarev et al.
CANCER RESEARCH (2009)
Increasing the Antigenicity of Synthetic Tumor-Associated Carbohydrate Antigens by Targeting Toll-Like Receptors
Sampat Ingale et al.
CHEMBIOCHEM (2009)
Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience
Jianglong Zhu et al.
EXPERT REVIEW OF VACCINES (2009)
From Synthesis to Biologics: Preclinical Data on a Chemistry Derived Anticancer Vaccine
Jianglong Zhu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes
Tanja Ninkovic et al.
MOLECULAR IMMUNOLOGY (2009)
Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer
Ann Willman Silk et al.
MOLECULAR IMMUNOLOGY (2009)
'Biologic' level structures through chemistry: a total synthesis of a unimolecular pentavalent MUCI glycopeptide construct
Dongjoo Lee et al.
TETRAHEDRON LETTERS (2009)
Mucins in cancer: function, prognosis and therapy
Donald W. Kufe
NATURE REVIEWS CANCER (2009)
Structure and function of the cell surface (tethered) mucins
Christine L. Hattrup et al.
ANNUAL REVIEW OF PHYSIOLOGY (2008)
Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)
Maria Moreno et al.
CANCER LETTERS (2008)
Immunoglobulin allotypes influence antibody responses to mucin 1 in patients with gastric cancer
Janardan P. Pandey et al.
CANCER RESEARCH (2008)
Strategies used for MUC1 immunotherapy: human clinical studies
Choon-Kit Tang et al.
EXPERT REVIEW OF VACCINES (2008)
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance
Paola Allavena et al.
IMMUNOLOGICAL REVIEWS (2008)
Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer
Angele L. M. Oei et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer
Hailing Lu et al.
JOURNAL OF PROTEOME RESEARCH (2008)
A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer
Elvira M. Davelaar et al.
TUMOR BIOLOGY (2008)
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel et al.
NATURE (2007)
A polyvalent vaccine for high-risk prostate patients: are more antigens better?
Susan F. Slovin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC)
Marfa Moreno et al.
CANCER LETTERS (2007)
MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion
Benjamin J. Swanson et al.
CANCER RESEARCH (2007)
Lessons from randomized phase III studies with active cancer immunotherapies - Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC)
Lothar H. Finke et al.
VACCINE (2007)
O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes
Tanja Ninkovic et al.
JOURNAL OF IMMUNOLOGY (2007)
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
Paul J. Sabbatini et al.
CLINICAL CANCER RESEARCH (2007)
Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation
B. B. J. Hermsen et al.
EUROPEAN JOURNAL OF CANCER (2007)
Autoantibodies in breast cancer: their use as an aid to early diagnosis
C. Chapman et al.
ANNALS OF ONCOLOGY (2007)
Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion
Lu-Gang Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Impact of Helicobacter pylori infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer
K. Klaamas et al.
IMMUNOLOGICAL INVESTIGATIONS (2007)
Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: Relation to survival
O. Kurtenkov et al.
ACTA ONCOLOGICA (2007)
A clinical development paradigm for cancer vaccines and related biologics
Axel Hoos et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma
Silvie Cloosen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis
Martin E. Rabassa et al.
BMC CANCER (2006)
Immunology of O-glycosylated proteins: Approaches to the design of a MUC1 glycopeptide-based tumor vaccine
Franz-Georg Hanisch et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2006)
Cancer vaccines targeting carbohydrate antigens
Philip O. Livingston et al.
HUMAN VACCINES (2006)
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission
RH Verheijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mannan-MUC1 - Pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma
BE Loveland et al.
CLINICAL CANCER RESEARCH (2006)
Cell surface-associated mucins in signal transduction
Pankaj K. Singh et al.
TRENDS IN CELL BIOLOGY (2006)
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
Vasso Apostolopoulos et al.
BREAST CANCER RESEARCH (2006)
Malignancy-induced autoimmunity to MUC1:: initial antibody characterization
CRL Graves et al.
JOURNAL OF PEPTIDE RESEARCH (2005)
Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses
S von Mensdorff-Pouilly et al.
GLYCOBIOLOGY (2005)
Vaccination with BLP25 lipsome vaccine to treat non-small cell lung and prostate cancers
Scott North et al.
EXPERT REVIEW OF VACCINES (2005)
Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity
G Ragupathi et al.
JOURNAL OF IMMUNOLOGY (2005)
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer
DW Cramer et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
MUC1 mucin-mediated regulation of human T cells
B Agrawal et al.
INTERNATIONAL IMMUNOLOGY (2005)
Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer:: Results at 4 years
MJ Slade et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer
RK Ramanathan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity
JS de Bono et al.
ANNALS OF ONCOLOGY (2004)
Increased expression of MUC1 in advanced pancreatic cancer
Y Hinoda et al.
JOURNAL OF GASTROENTEROLOGY (2003)
O-linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells
FG Hanisch et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Hypervariability of the membrane-associated mucin and cancer marker MUC1
JC Fowler et al.
HUMAN GENETICS (2003)
Tissue and serum MUC1 mucin detection in breast cancer patients
MV Croce et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer
Y Hamanaka et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: Processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells
AM Vlad et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Altered expression and allelic association of the hypervariable membrane mucin MUC1 in Helicobacter pylori gastritis
LE Vinall et al.
GASTROENTEROLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy
U Keilholz et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Overexpression of MUC1 reconfigures the binding properties of tumor cells
KM McDermott et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form
RL ten Berge et al.
JOURNAL OF CLINICAL PATHOLOGY (2001)
Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1
K Engelmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients
FGM Snijdewint et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Maternal serum CA125 and CA15-3 antigen levels in normal and pathological pregnancy
GG Bon et al.
FETAL DIAGNOSIS AND THERAPY (2001)
Mannan mucin-1 peptide immunization: Influence of cyclophosphamide and the route of injection
V Karanikas et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women
MV Croce et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
Mucins and immune reactions to mucins in ulcerative colitis
T Hayashi et al.
DIGESTION (2001)
MUC1 mucin core protein binds to the domain 1 of ICAM-1
T Hayashi et al.
DIGESTION (2001)
Human MUC1 mucin: a multifaceted glycoprotein
S von Mensdorff-Pouilly et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2000)
MUC1 in carcinoma-host interactions
K Denda-Nagai et al.
GLYCOCONJUGATE JOURNAL (2000)
Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin
S von Mensdorff-Pouilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer
Y Hirasawa et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues
PO Livingston et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2000)
Circulating autoantibodies against purified colonic mucin in ulcerative colitis
H Takaishi et al.
JOURNAL OF GASTROENTEROLOGY (2000)
Share Paper
